The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The Nationwide Complete Most cancers Community (NCCN) Medical Observe Pointers in Oncology now embrace Besremi (ropeginterferon alfa-2b-njft) as a Class 1 most...
New knowledge from a randomized part 2 medical trial counsel that including the focused remedy onvansertib to straightforward first-line therapy could enhance...
Throughout an interview with CURE, Dr. Tracy Proverbs-Singh, a gastrointestinal oncologist at John Theurer Most cancers Middle, mentioned how she helps sufferers...
